title: Reversible bone marrow necrosis after all-trans retinoic acid induction therapy for acute promyelocytic leukaemia.
authors.forename: S
authors.initials: S
authors.lastname: Lakhwani
authors.forename: J M
authors.initials: JM
authors.lastname: Raya
authors.forename: G
authors.initials: G
authors.lastname: González-Brito
authors.forename: H
authors.initials: H
authors.lastname: Álvarez-Argüelles
authors.forename: M L
authors.initials: ML
authors.lastname: Brito
authors.forename: L
authors.initials: L
authors.lastname: Hernández-Nieto
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001854:Bone Marrow Cells / Q000473:pathology*; D004761:Enterocolitis, Pseudomembranous / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D009336:Necrosis; D020127:Recovery of Function; D012074:Remission Induction; D014212:Tretinoin / Q000009:adverse effects* / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D014212:Tretinoin; D014640:Vancomycin; D015122:Mercaptopurine; D008727:Methotrexate; D015255:Idarubicin